ArticleThe Journal of dermatology2026
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective Study.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Neutrophil Percentage-Albumin Ratio in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for malignant melanoma (MM). However, given variable response rates and potential toxicities, identifying robust biomarkers is crucial. We investigated whether the modified Glasgow Prognostic Score (mGPS) predicts treatment efficacy and toxicity in Asian patients with advanced MM receiving first-line ICIs. We retrospectively analyzed 132 patients with stage IV MM treated at Shizuoka Cancer Center between 2012 and 2024. Patients were stratified by mGPS, which integrates C-reactive protein and albumin levels. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and the incidence of severe adverse events. The cohort was distributed as mGPS0 (70.5%), mGPS1 (12.9%), and mGPS2 (16.7%). Treatment efficacy declined notably with higher scores: ORR was 28.0% for mGPS0 and 23.5% for mGPS1, but dropped to 4.5% for mGPS2. Survival analysis revealed a clear prognostic stratification; median PFS was 6.2, 2.5, and 1.5 months, and median OS was 23.5, 14.6, and 1.9 months for mGPS0, mGPS1, and mGPS2, respectively. The mGPS2 group demonstrated significantly worse survival outcomes compared to the mGPS0 group. Conversely, the incidence of grade ≥ 3 adverse events did not differ significantly among the categories. The mGPS is a simple, accessible biomarker reflecting systemic inflammation and nutritional status. It effectively predicts ICI treatment outcomes in patients with advanced MM, particularly identifying those with mGPS2 as having a significantly poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.